A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab

BACKGROUND: At present, there is a lack of studies focusing on the survival prediction of patients with non-small cell lung cancer (NSCLC) receiving atezolizumab in light of gene mutation characteristic. METHODS: Patients with NSCLC receiving atezolizumab from the OAK study were defined as the train...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jiamao, Wang, Xiaohui, Zhang, Chenyue, Bu, Shuai, Zhao, Chenglong, Wang, Haiyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261129/
https://www.ncbi.nlm.nih.gov/pubmed/34248926
http://dx.doi.org/10.3389/fimmu.2021.606027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261129/
https://www.ncbi.nlm.nih.gov/pubmed/34248926
http://dx.doi.org/10.3389/fimmu.2021.606027

Ejemplares similares